Points to Consider No.9 Lessons Learned from the COVID-19 Pandemic
Premium Members: to claim your annual free technical document download, email membership@pda.org and indicate the document you wish to claim.
- Format
- PDF Single User
- Member Price
- $180.00
- Nonmember Price
- $325.00
- Government Price
- $180.00
Please sign in or become a member to purchase items from the PDA bookstore.
As a result of the COVID-19 pandemic, many industries-the pharmaceutical included-went through a substantial disruption.Some of these disruptions included facility shutdowns, unprecedented supply chain challanges, worker availabitlity, and quality system limitations (e.g. physical signatures, investigations, document originals, risk assessments, audits.) For many pharmaceutical companies, challanges increased as they raced to provide a vaccine or a therapeutic treatment for COVID-19. Their manufacturing operations were changed over to accommodate the creation of the vaccine and, in order to get the vaccine to patients quickly, many logistical challanges arose.
This document provides lessons learned from the COVID-19 pandemic to pharmaceutical manufacturing. Areas covered include manufacturing, people, quality, regulatory and supply chain.
Table of Contents
Introduction
I. Manufacturing
II. People
III. Quality
IV. Regulatory
V. Supply Chain
VI. Relevant Vendor and Supplier Resources
About the Authors